NASDAQ:FHTX Foghorn Therapeutics (FHTX) Stock Price, News & Analysis → My top 100 stocks… (From DTI) (Ad) Free FHTX Stock Alerts $5.49 +0.26 (+4.97%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$5.16▼$5.5550-Day Range$5.05▼$8.0052-Week Range$2.70▼$9.97Volume35,367 shsAverage Volume79,102 shsMarket Capitalization$233.71 millionP/E RatioN/ADividend YieldN/APrice Target$14.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Foghorn Therapeutics alerts: Email Address Foghorn Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside164.1% Upside$14.50 Price TargetShort InterestBearish6.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.05) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 starsMedical Sector691st out of 915 stocksPharmaceutical Preparations Industry315th out of 423 stocks 3.3 Analyst's Opinion Consensus RatingFoghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFoghorn Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.31% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Foghorn Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFoghorn Therapeutics does not currently pay a dividend.Dividend GrowthFoghorn Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FHTX. Previous Next 1.1 News and Social Media Coverage Search Interest6 people have searched for FHTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.23% of the stock of Foghorn Therapeutics is held by insiders.Percentage Held by Institutions61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Foghorn Therapeutics are expected to grow in the coming year, from ($2.05) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foghorn Therapeutics is -2.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foghorn Therapeutics is -2.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Foghorn Therapeutics Stock (NASDAQ:FHTX)Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FHTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FHTX Stock News HeadlinesApril 18, 2024 | bizjournals.comPetri Dish: Non-viral vector startup launch; Foghorn’s new CFOApril 16, 2024 | marketwatch.comFoghorn Therapeutics Taps Kristian Humer as Finance ChiefApril 28, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 16, 2024 | globenewswire.comFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerApril 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)April 10, 2024 | markets.businessinsider.comFoghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic AlliancesApril 9, 2024 | globenewswire.comFoghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology ProgramsApril 9, 2024 | finance.yahoo.comFoghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth PlansApril 28, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 5, 2024 | finance.yahoo.comFoghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare ConferenceApril 5, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare ConferenceApril 4, 2024 | finance.yahoo.comFed commentary, jobless claims data: What to WatchMarch 26, 2024 | globenewswire.comFoghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual MeetingMarch 8, 2024 | bizjournals.comCambridge biotech discloses it quietly laid off 28% of its staff last yearMarch 7, 2024 | investorplace.comFHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | benzinga.comFoghorn Therapeutics: Q4 Earnings InsightsMarch 7, 2024 | finanznachrichten.deFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic OutlookMarch 7, 2024 | globenewswire.comFoghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic OutlookMarch 5, 2024 | globenewswire.comFoghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909February 28, 2024 | finance.yahoo.comFoghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Cowen's 44th Annual Health Care ConferenceFebruary 26, 2024 | thestreet.comFoghorn Therapeutics Inc.February 15, 2024 | investing.comFoghorn Therapeutics Inc (FHTX)February 12, 2024 | finance.yahoo.comFoghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?February 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)February 9, 2024 | finance.yahoo.comFoghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 DevelopmentFebruary 9, 2024 | msn.comFoghorn Therapeutics Releases New Investor PresentationSee More Headlines Receive FHTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FHTX CUSIPN/A CIK1822462 Webfoghorntx.com Phone617-586-3100FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$14.50 High Stock Price Target$20.00 Low Stock Price Target$6.00 Potential Upside/Downside+164.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,430,000.00 Net Margins-288.17% Pretax Margin-275.80% Return on EquityN/A Return on Assets-30.01% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual Sales$34.15 million Price / Sales6.84 Cash FlowN/A Price / Cash FlowN/A Book Value($1.83) per share Price / Book-3.00Miscellaneous Outstanding Shares42,570,000Free Float38,637,000Market Cap$233.71 million OptionableOptionable Beta3.13 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Adrian H. B. Gottschalk (Age 48)President, CEO & Director Comp: $784.65kDr. Steven F. Bellon Ph.D. (Age 59)Chief Scientific Officer Comp: $572.6kDr. Alfonso Quintas Cardama M.D. (Age 52)Chief Medical Officer Comp: $300.16kDr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory BoardMs. Karin HellsvikVP, Corporate Affairs & Investor RelationsMr. Michael J. LaCascia (Age 59)Chief Legal Officer Comp: $565.5kMr. Saurabh Sewak Ph.D.Vice President of Corporate DevelopmentMr. Carlos Costa (Age 50)Chief People Officer Ms. Fanny Cavalie (Age 46)Chief Strategy & Business Operations Officer More ExecutivesKey CompetitorsG1 TherapeuticsNASDAQ:GTHXImmutepNASDAQ:IMMPAcrivon TherapeuticsNASDAQ:ACRVGeneration BioNASDAQ:GBIOMerrimack PharmaceuticalsNASDAQ:MACKView All CompetitorsInsiders & InstitutionsRaymond James & AssociatesBought 162,069 shares on 4/22/2024Ownership: 5.240%Rockwood Wealth Management LLCSold 107,348 shares on 4/22/2024Ownership: 0.252%Birchview Capital LPBought 56,087 shares on 2/15/2024Ownership: 0.760%Alta Wealth Advisors LLCBought 30,032 shares on 2/12/2024Ownership: 0.071%Panagora Asset Management Inc.Bought 62,441 shares on 2/8/2024Ownership: 0.230%View All Insider TransactionsView All Institutional Transactions FHTX Stock Analysis - Frequently Asked Questions Should I buy or sell Foghorn Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FHTX shares. View FHTX analyst ratings or view top-rated stocks. What is Foghorn Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued twelve-month target prices for Foghorn Therapeutics' shares. Their FHTX share price targets range from $6.00 to $20.00. On average, they expect the company's stock price to reach $14.50 in the next year. This suggests a possible upside of 164.1% from the stock's current price. View analysts price targets for FHTX or view top-rated stocks among Wall Street analysts. How have FHTX shares performed in 2024? Foghorn Therapeutics' stock was trading at $6.45 on January 1st, 2024. Since then, FHTX shares have decreased by 14.9% and is now trading at $5.49. View the best growth stocks for 2024 here. When is Foghorn Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our FHTX earnings forecast. How were Foghorn Therapeutics' earnings last quarter? Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.22. The firm earned $5.77 million during the quarter, compared to the consensus estimate of $4.91 million. What ETFs hold Foghorn Therapeutics' stock? ETFs with the largest weight of Foghorn Therapeutics (NASDAQ:FHTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). When did Foghorn Therapeutics IPO? Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Foghorn Therapeutics' major shareholders? Foghorn Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Raymond James & Associates (5.24%) and Rockwood Wealth Management LLC (0.25%). View institutional ownership trends. How do I buy shares of Foghorn Therapeutics? Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FHTX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
